Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TPST-1495 |
Trade Name | |
Synonyms | TPST1495|TPST 1495 |
Drug Descriptions |
TPST-1495 is a dual antagonist that selectively inhibits EP2 and EP4, and reverses Prostaglandin E2 mediated immune suppression, potentially resulting in enhanced antitumor immune response and tumor growth inhibition (Journal for ImmunoTherapy of Cancer 2019;7:282, Abs nr: P311). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C174460 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + TPST-1495 | Pembrolizumab TPST-1495 | 0 | 1 |
TPST-1495 | TPST-1495 | 0 | 2 |
TPST-1495 + unspecified PD-1 antibody | TPST-1495 unspecified PD-1 antibody | 0 | 0 |